Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).
about
Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression ModelUnderstanding Advanced Prostate Cancer Decision Making Utilizing an Interactive Decision Aid.Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerCirculating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American menSipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.Decreased Cancer Mortality-to-Incidence Ratios with Increased Accessibility of Federally Qualified Health CentersHighly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer.Difference of opinion - Radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: YesThe role of miR-24 as a race related genetic factor in prostate cancer.Management of metastatic hormone-sensitive prostate cancer.Understanding the role of new systemic agents in the treatment of prostate cancer.Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients.CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers.Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer.Clinical features and treatment strategies for older prostate cancer patients with bone metastasis.MRI should be routine for all patients with localized prostate cancer? | Opinion: Yes.No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period.Metastatic epidural spinal cord compression among elderly patients with advanced prostate cancer.Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases.Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease VolumeTime of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)
P2860
Q26783861-B65D4231-6EDF-4B47-86AB-37D68AB61E41Q30275497-97ECD986-9BF3-4E7C-836E-31FECA5ADE57Q30278902-94A18513-159D-46FF-B90A-E2FC635BAE27Q30574916-142DB5C4-DFCC-47CA-A84D-90BE154A16BEQ33656791-D3DC984F-4321-44BF-9E93-B648A845DDD1Q34171025-5AE1E5D8-0548-4454-B69D-8B73F16F4BF1Q34787165-C2B0F6FE-1B76-424E-AF91-2D4D90DD8EA5Q35099127-B6B6EF70-674B-4379-8487-5EF97CA44838Q35815537-962426A5-E065-409D-8F9E-2B8EB78F7FE5Q35987354-403CC390-5EB8-4A53-BC62-E3375804A79CQ37344327-F6DDE7E9-47D7-4109-8291-715261D029D8Q37725482-E56590D2-EAF0-48D1-9C5D-61D0C923482BQ38353835-5D9A0D0F-BCE0-4341-B7E9-CDAFD025349CQ38973445-BE0DBC8A-4F78-42F5-AA97-1FBCD6465F51Q39038671-310F9026-2F95-41E1-ABDC-51EBCD906C3DQ39222023-CEEC6325-E390-4419-8551-5C6B6243619AQ40591427-7BC792EF-5C46-4205-918F-B5D0E12919ABQ41137092-434E0E31-AAE0-4321-8B45-FDED8CE6317BQ42096361-88F7EE3C-6658-438D-BF33-AA468DBB262BQ42140216-2E1AB352-D8C7-4B79-9737-20D6AE741485Q42365092-AA5104FF-2CD1-4923-9031-38AE6CD35CA4Q46097187-F421B913-5D10-4495-AF32-682387B2EC47Q46820544-50BDFF38-583A-47F6-996E-BC2CA16F8C16Q48037073-C3DA824F-5E2A-41AD-B171-D9FCB151F102Q48320211-0CBEC4B1-A631-419D-8952-D55DC7C8E7E9Q55640456-5B35A71A-E29A-4DD4-BAF1-445E858AA6CEQ57165997-6E898B7F-E005-410C-9B43-51314E5F68D8
P2860
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Improved overall survival tren ...... ence (S8494, S8894 and S9346).
@ast
Improved overall survival tren ...... ence (S8494, S8894 and S9346).
@en
type
label
Improved overall survival tren ...... ence (S8494, S8894 and S9346).
@ast
Improved overall survival tren ...... ence (S8494, S8894 and S9346).
@en
prefLabel
Improved overall survival tren ...... ence (S8494, S8894 and S9346).
@ast
Improved overall survival tren ...... ence (S8494, S8894 and S9346).
@en
P2093
P2860
P1476
Improved overall survival tren ...... ence (S8494, S8894 and S9346).
@en
P2093
Bryan J Donnelly
Catherine M Tangen
Celestia S Higano
E David Crawford
Eric J Small
Ian M Thompson
Isaac J Powell
Maha H A Hussain
Mario A Eisenberger
Nicholas J Vogelzang
P2860
P304
P356
10.1016/J.JURO.2012.06.046
P407
P577
2012-08-22T00:00:00Z